Symbols / CADL $4.99 +6.85%
CADL Chart
About
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 365.50M |
| Enterprise Value | 294.81M | Income | -38.18M | Sales | — |
| Book/sh | 0.95 | Cash/sh | 1.64 | Dividend Yield | — |
| Payout | 0.00% | Employees | 55 | IPO | — |
| P/E | — | Forward P/E | -7.80 | PEG | — |
| P/S | — | P/B | 5.27 | P/C | — |
| EV/EBITDA | -6.23 | EV/Sales | — | Quick Ratio | 13.31 |
| Current Ratio | 13.49 | Debt/Eq | 94.44 | LT Debt/Eq | — |
| EPS (ttm) | -0.72 | EPS next Y | -0.64 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-12 | ROA | -25.95% |
| ROE | -64.58% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 73.25M |
| Shs Float | 63.31M | Short Float | 21.01% | Short Ratio | 10.85 |
| Short Interest | — | 52W High | 9.08 | 52W Low | 4.25 |
| Beta | -0.90 | Avg Volume | 1.01M | Volume | 1.49M |
| Target Price | $18.38 | Recom | Strong_buy | Prev Close | $4.67 |
| Price | $4.99 | Change | 6.85% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$18.38
Mean price target
2. Current target
$4.99
Latest analyst target
3. DCF / Fair value
$-11.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.99
Low
$7.00
High
$25.00
Mean
$18.38
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | main | Citigroup | Buy → Buy | $22 |
| 2026-03-13 | main | Canaccord Genuity | Buy → Buy | $25 |
| 2025-12-08 | reit | Stephens & Co. | Overweight → Overweight | $15 |
| 2025-11-14 | main | Citigroup | Buy → Buy | $24 |
| 2025-10-28 | init | Stephens & Co. | — → Overweight | $15 |
| 2025-10-21 | init | LifeSci Capital | — → Outperform | $16 |
| 2025-09-29 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-09-03 | down | B of A Securities | Buy → Neutral | $7 |
| 2025-04-11 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-02-26 | main | Canaccord Genuity | Buy → Buy | $25 |
| 2025-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-02-20 | init | Citigroup | — → Buy | $25 |
| 2025-02-19 | init | Canaccord Genuity | — → Buy | $20 |
| 2025-02-07 | init | B of A Securities | — → Buy | $15 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2024-11-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-05-15 | main | BMO Capital | Outperform → Outperform | $3 |
- Half of lung cancer patients alive 2 years in Candel immunotherapy study - Stock Titan ue, 17 Mar 2026 12
- Responsive Playbooks and the CADL Inflection - Stock Traders Daily Sat, 14 Mar 2026 06
- Candel Therapeutics (NASDAQ:CADL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat Fri, 13 Mar 2026 19
- Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire hu, 12 Mar 2026 12
- $CADL stock is up 15% today. Here's what we see in our data. - Nasdaq Wed, 09 Jul 2025 07
- Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance Mon, 02 Jun 2025 07
- Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $22.00 - MarketBeat Fri, 13 Mar 2026 20
- New Candel Therapeutics hire gets 20,000 stock options at $5.25 - Stock Titan Mon, 02 Mar 2026 08
- FY2030 Earnings Forecast for CADL Issued By HC Wainwright - MarketBeat Mon, 16 Mar 2026 05
- Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL - MarketBeat Sat, 14 Mar 2026 09
- Cancer biotech Candel prices $100M sale to back prostate launch prep, lung trial - Stock Titan hu, 19 Feb 2026 08
- Candel Therapeutics CEO to speak at TD Cowen Boston conference - Stock Titan ue, 24 Feb 2026 08
- Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7% - MarketBeat Sat, 14 Mar 2026 18
- Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat hu, 12 Mar 2026 15
- CADL SEC Filings - Candel Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 04 Mar 2026 18
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 550458 | 2999996 | — | Purchase at price 5.45 per share. | MANNING PAUL B. | Director | — | 2026-02-23 00:00:00 | I |
| 1 | 937 | 1209 | — | Conversion of Exercise of derivative security at price 1.29 per share. | NICHOLS WILLIAMS GARRETT | Officer | — | 2025-07-28 00:00:00 | D |
| 2 | 937 | 6540 | — | Sale at price 6.98 per share. | NICHOLS WILLIAMS GARRETT | Officer | — | 2025-07-28 00:00:00 | D |
| 3 | 781 | 1007 | — | Conversion of Exercise of derivative security at price 1.29 per share. | NICHOLS WILLIAMS GARRETT | Officer | — | 2025-06-30 00:00:00 | D |
| 4 | 781 | 3936 | — | Sale at price 5.04 per share. | NICHOLS WILLIAMS GARRETT | Officer | — | 2025-06-30 00:00:00 | D |
| 5 | 64239 | 299996 | — | Stock Award(Grant) at price 4.67 per share. | PAPA JOSEPH C | Director | — | 2025-06-25 00:00:00 | I |
| 6 | 1070663 | 4999996 | — | Stock Award(Grant) at price 4.67 per share. | MANNING PAUL B. | Director | — | 2025-06-25 00:00:00 | I |
| 7 | 5353 | 24999 | — | Stock Award(Grant) at price 4.67 per share. | NABEL GARY J. | Director | — | 2025-06-25 00:00:00 | D |
| 8 | 111349 | 520000 | — | Stock Award(Grant) at price 4.67 per share. | MARTELL CHRISTOPHER | Director | — | 2025-06-25 00:00:00 | I |
| 9 | 42826 | 199997 | — | Stock Award(Grant) at price 4.67 per share. | TAK PAUL PETER | Chief Executive Officer | — | 2025-06-25 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -43.42M | -31.30M | -35.35M | -32.68M |
| TotalUnusualItems | 8.20M | -20.80M | 966.00K | 16.37M |
| TotalUnusualItemsExcludingGoodwill | 8.20M | -20.80M | 966.00K | 16.37M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -38.18M | -55.18M | -37.94M | -18.79M |
| ReconciledDepreciation | 845.00K | 990.00K | 960.00K | 778.00K |
| EBITDA | -35.22M | -52.10M | -34.38M | -16.31M |
| EBIT | -36.06M | -53.09M | -35.34M | -17.09M |
| NetInterestIncome | 1.80M | -1.00M | -514.00K | -490.00K |
| InterestExpense | 2.12M | 2.09M | 2.60M | 1.71M |
| InterestIncome | 3.92M | 1.09M | 2.08M | 1.22M |
| NormalizedIncome | -46.38M | -34.38M | -38.91M | -35.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -38.18M | -55.18M | -37.94M | -18.79M |
| TotalExpenses | 48.18M | 33.37M | 38.39M | 34.80M |
| RentExpenseSupplemental | 194.00K | 192.00K | 161.00K | 184.00K |
| TotalOperatingIncomeAsReported | -48.27M | -33.37M | -38.39M | -34.72M |
| DilutedAverageShares | 31.68M | 28.94M | 28.82M | 18.87M |
| BasicAverageShares | 31.68M | 28.94M | 28.82M | 18.87M |
| DilutedEPS | -1.74 | -1.31 | -0.65 | -1.91 |
| BasicEPS | -1.74 | -1.31 | -0.65 | -1.91 |
| DilutedNIAvailtoComStockholders | -38.18M | -55.18M | -37.94M | -18.79M |
| NetIncomeCommonStockholders | -38.18M | -55.18M | -37.94M | -18.79M |
| NetIncome | -38.18M | -55.18M | -37.94M | -18.79M |
| NetIncomeIncludingNoncontrollingInterests | -38.18M | -55.18M | -37.94M | -18.79M |
| NetIncomeContinuousOperations | -38.18M | -55.18M | -37.94M | -18.79M |
| PretaxIncome | -38.18M | -55.18M | -37.94M | -18.79M |
| OtherIncomeExpense | 8.20M | -20.80M | 966.00K | 16.37M |
| GainOnSaleOfSecurity | 8.20M | -20.80M | 966.00K | 16.37M |
| NetNonOperatingInterestIncomeExpense | 1.80M | -1.00M | -514.00K | -490.00K |
| TotalOtherFinanceCost | 490.00K | 53.00K | ||
| InterestExpenseNonOperating | 2.12M | 2.09M | 2.60M | 1.71M |
| InterestIncomeNonOperating | 3.92M | 1.09M | 2.08M | 1.22M |
| OperatingIncome | -48.18M | -33.37M | -38.39M | -34.67M |
| OperatingExpense | 48.18M | 33.37M | 38.39M | 34.80M |
| OtherOperatingExpenses | -89.00K | -48.00K | -1.08M | |
| ResearchAndDevelopment | 30.50M | 19.31M | 24.51M | 20.79M |
| SellingGeneralAndAdministration | 17.77M | 14.06M | 13.88M | 14.06M |
| GeneralAndAdministrativeExpense | 17.77M | 14.06M | 13.88M | 14.06M |
| OtherGandA | 8.94M | 5.85M | 4.39M | 4.26M |
| InsuranceAndClaims | 988.00K | 1.19M | 1.60M | 2.38M |
| RentAndLandingFees | 194.00K | 192.00K | 161.00K | 184.00K |
| SalariesAndWages | 7.64M | 6.83M | 7.73M | 7.23M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 125.00K |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 125.00K |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 122.61K | 122.61K | 122.61K | 122.61K |
| OrdinarySharesNumber | 54.90M | 46.81M | 29.09M | 28.92M |
| ShareIssued | 55.02M | 46.93M | 29.21M | 29.04M |
| TotalDebt | 49.03M | 13.47M | 22.76M | 22.80M |
| TangibleBookValue | 51.92M | 66.33M | 12.74M | 47.71M |
| InvestedCapital | 99.05M | 78.83M | 34.02M | 68.56M |
| WorkingCapital | 112.39M | 66.28M | 22.61M | 66.33M |
| NetTangibleAssets | 51.92M | 66.33M | 12.74M | 47.71M |
| CapitalLeaseObligations | 1.90M | 973.00K | 1.49M | 1.95M |
| CommonStockEquity | 51.92M | 66.33M | 12.74M | 47.71M |
| TotalCapitalization | 99.05M | 68.93M | 25.13M | 68.56M |
| TotalEquityGrossMinorityInterest | 51.92M | 66.33M | 12.74M | 47.71M |
| StockholdersEquity | 51.92M | 66.33M | 12.74M | 47.71M |
| TreasuryStock | 448.00K | 448.00K | 448.00K | 448.00K |
| RetainedEarnings | -230.39M | -192.21M | -137.03M | -99.09M |
| AdditionalPaidInCapital | 282.21M | 258.51M | 149.93M | 146.96M |
| CapitalStock | 550.00K | 469.00K | 290.00K | 290.00K |
| CommonStock | 550.00K | 469.00K | 290.00K | 290.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 73.27M | 40.54M | 28.46M | 29.98M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 64.28M | 3.01M | 14.27M | 24.36M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DerivativeProductLiabilities | 15.60M | 0.00 | 916.00K | 1.88M |
| NonCurrentDeferredLiabilities | 89.00K | 0.00 | 0.00 | 144.00K |
| NonCurrentDeferredRevenue | 89.00K | 0.00 | 0.00 | 144.00K |
| LongTermDebtAndCapitalLeaseObligation | 48.59M | 3.01M | 13.36M | 22.34M |
| LongTermCapitalLeaseObligation | 1.46M | 407.00K | 973.00K | 1.49M |
| LongTermDebt | 47.13M | 2.60M | 12.38M | 20.85M |
| CurrentLiabilities | 9.00M | 37.53M | 14.18M | 5.62M |
| OtherCurrentLiabilities | 89.00K | 21.72M | 48.00K | 334.00K |
| CurrentDebtAndCapitalLeaseObligation | 445.00K | 10.46M | 9.41M | 464.00K |
| CurrentCapitalLeaseObligation | 445.00K | 566.00K | 513.00K | 464.00K |
| CurrentDebt | 9.89M | 8.89M | ||
| OtherCurrentBorrowings | 9.89M | 8.89M | ||
| LineOfCredit | 0.00 | |||
| PayablesAndAccruedExpenses | 8.46M | 5.35M | 4.78M | 5.10M |
| CurrentAccruedExpenses | 7.33M | 5.11M | 4.36M | 4.72M |
| Payables | 1.13M | 237.00K | 422.00K | 380.00K |
| AccountsPayable | 1.13M | 237.00K | 422.00K | 380.00K |
| TotalAssets | 125.19M | 106.87M | 41.20M | 77.69M |
| TotalNonCurrentAssets | 3.81M | 3.06M | 4.40M | 5.75M |
| OtherNonCurrentAssets | 503.00K | 329.00K | 382.00K | 266.00K |
| NetPPE | 3.30M | 2.73M | 4.02M | 5.48M |
| AccumulatedDepreciation | -3.56M | -3.08M | -2.09M | -1.13M |
| GrossPPE | 6.86M | 5.81M | 6.11M | 6.61M |
| Leases | 3.01M | 3.11M | 3.11M | 3.06M |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 3.47M | 2.46M | 2.75M | 3.31M |
| MachineryFurnitureEquipment | 386.00K | 244.00K | 247.00K | 240.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 121.39M | 103.80M | 36.80M | 71.94M |
| OtherCurrentAssets | 1.66M | 1.15M | 1.38M | 1.89M |
| PrepaidAssets | 2.30M | |||
| CashCashEquivalentsAndShortTermInvestments | 119.73M | 102.65M | 35.41M | 70.06M |
| CashAndCashEquivalents | 119.73M | 102.65M | 35.41M | 70.06M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -38.90M | -27.04M | -34.70M | -32.72M |
| RepaymentOfDebt | -11.73M | -9.17M | 0.00 | |
| IssuanceOfDebt | 47.95M | 0.00 | 0.00 | 19.91M |
| IssuanceOfCapitalStock | 19.37M | 101.76M | 0.00 | 0.00 |
| CapitalExpenditure | -587.00K | -16.00K | -457.00K | -1.30M |
| InterestPaidSupplementalData | 1.28M | 1.79M | 2.15M | 1.15M |
| IncomeTaxPaidSupplementalData | 0.00 | 183.00K | 29.00K | |
| EndCashPosition | 120.15M | 102.92M | 35.68M | 70.32M |
| BeginningCashPosition | 102.92M | 35.68M | 70.32M | 83.07M |
| ChangesInCash | 17.23M | 67.24M | -34.65M | -12.74M |
| FinancingCashFlow | 56.10M | 94.28M | -121.00K | 19.97M |
| CashFlowFromContinuingFinancingActivities | 56.10M | 94.28M | -121.00K | 19.97M |
| NetOtherFinancingCharges | -121.00K | |||
| ProceedsFromStockOptionExercised | 516.00K | 1.69M | 0.00 | 64.00K |
| NetCommonStockIssuance | 19.37M | 101.76M | 0.00 | 0.00 |
| CommonStockIssuance | 19.37M | 101.76M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 36.21M | -9.17M | 0.00 | 19.91M |
| NetLongTermDebtIssuance | 36.21M | -9.17M | 0.00 | 19.91M |
| LongTermDebtPayments | -11.73M | -9.17M | 0.00 | |
| LongTermDebtIssuance | 47.95M | 0.00 | 0.00 | 19.91M |
| InvestingCashFlow | -560.00K | -16.00K | -280.00K | -1.30M |
| CashFlowFromContinuingInvestingActivities | -560.00K | -16.00K | -280.00K | -1.30M |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | |||
| NetPPEPurchaseAndSale | -560.00K | -16.00K | -280.00K | -1.30M |
| SaleOfPPE | 27.00K | 0.00 | 177.00K | 0.00 |
| PurchaseOfPPE | -587.00K | -16.00K | -457.00K | -1.30M |
| OperatingCashFlow | -38.31M | -27.02M | -34.24M | -31.42M |
| CashFlowFromContinuingOperatingActivities | -38.31M | -27.02M | -34.24M | -31.42M |
| ChangeInWorkingCapital | 2.19M | 346.00K | -525.00K | 71.00K |
| ChangeInOtherWorkingCapital | 178.00K | -192.00K | 67.00K | 285.00K |
| ChangeInOtherCurrentLiabilities | -509.00K | -513.00K | -464.00K | -464.00K |
| ChangeInOtherCurrentAssets | -24.00K | 53.00K | -116.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 3.06M | 572.00K | -256.00K | 52.00K |
| ChangeInAccruedExpense | 2.25M | 757.00K | -301.00K | 1.26M |
| ChangeInPayable | 802.00K | -185.00K | 45.00K | -1.21M |
| ChangeInAccountPayable | 802.00K | -185.00K | 45.00K | -1.21M |
| ChangeInPrepaidAssets | -508.00K | 234.00K | 503.00K | 416.00K |
| OtherNonCashItems | 819.00K | 663.00K | 666.00K | 589.00K |
| StockBasedCompensation | 3.82M | 5.31M | 3.09M | 2.31M |
| AssetImpairmentCharge | 90.00K | 41.00K | 390.00K | 0.00 |
| DepreciationAmortizationDepletion | 845.00K | 990.00K | 960.00K | 778.00K |
| DepreciationAndAmortization | 845.00K | 990.00K | 960.00K | 778.00K |
| Depreciation | 845.00K | 990.00K | 960.00K | 778.00K |
| OperatingGainsLosses | -7.89M | 20.80M | -887.00K | -16.37M |
| GainLossOnInvestmentSecurities | -8.20M | 20.80M | -966.00K | -16.37M |
| GainLossOnSaleOfPPE | 306.00K | 0.00 | 79.00K | 0.00 |
| NetIncomeFromContinuingOperations | -38.18M | -55.18M | -37.94M | -18.79M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CADL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|